English High Court denies Mylan a stay in Neurim litigation
02-11-2021
English appeals court refuses Neurim injunction for insomnia drug
26-06-2020
Questions on Neurim scope remain post-SPC ruling, say lawyers
25-03-2019
ricochet64 / Shutterstock.com
Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Neurim, Mylan, insomnia, Flynn, generic, patent, novel, obvious, prior art, melatonin
